The former Novartis Oncology CEO will oversee the FDA approval and launch of UroGen's lead asset, UGN-101, for low-grade upper tract urothelial cancer, and build out the company's longer-term strategy. Scrip talked to Barrett about the transition from big pharma leadership to the CEO of a small biopharma.
Former Novartis AG Oncology CEO Liz Barrett will be the new CEO of the urology cancer specialist UroGen Pharma Ltd., the company announced Jan. 3, where she will be responsible for overseeing the FDA approval and launch of the company's first drug, now in late-stage development for low-grade upper tract urothelial cancer.
The news comes just about two weeks after Novartis announced Barrett's surprising departure after less than a year at the...
The CEO of South Korean biotech shares how his company was able to reach a partnership with Rani so quickly and why it is confident in its GLP-1/GLP-2 dual agonist for obesity and diabetes, despite recent disappointing clinical results for its sole rival.
The big pharma CEO with the highest-valued compensation in 2024 was David Ricks of Eli Lilly, while Pfizer and J&J executives slipped into third and fourth place behind AbbVie's now retired chief Richard Gonzalez. European firms brought up the rear.
Amgen’s Imdelltra for small-cell lung cancer is one of two bispecific T-cell engagers approved for solid tumors, but data at the WCLC meeting show other DLL3-targeting BiTEs may be on the way.
An academic study of GLP-1 agonist showed promise in patients with the painful skin condition but with no signs that the Danish drugmaker will pursue the indication, smaller players in the space may be interested.
Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
